Effectiveness in Treating Bronchial thermoplasty of Severe Asthma

Long-term safety data for research in severe asthma (RISA) trial, demonstrating is the maintenance of stable lung function and the absence of clinical complications in a period of five years in patients with severe refractory asthma Alair ® Bronchial thermoplasty system. RISA trial is the third in a series of trials that have completed the five year follow up of patients with bronchial thermoplasty (BT) treatment.

The results were presented at the annual meeting of the American Thoracic Society (ATS) in Denver by Ian Pavord, MD, professor of medicine at the University of Leicester, United Kingdom and RISA trial principal investigator.

"Recommend With the addition of these new long-term data, I can safely bad asthma patients with bronchial thermoplasty drugs, a strong safety profile for at least five years shows the controls," said Dr. Pavord. "The Alair System provides a novel combination treatment option for the use of inhaled corticosteroids and long acting beta agonists to provide long-term improvement in asthma control in general."
BT is a bronchoscopy procedure under moderate sedation performed on an outpatient basis. The Alair System provides thermal energy to the airway wall in a precisely controlled to reduce excessive smooth muscle cells of the respiratory tract. Was developed for the airways tighten the ability to reduce, thereby asthma attack frequency and severity.

The presentation of safety data from five years of RISA test follows two recently published peer-reviewed articles that support the positive long-term results after bronchial thermoplasty:

    * In February report in the journal BMC Pulmonary Medicine safety off the air five years of the study, a randomized controlled trial comparing BT standard treatment for patients with moderate to severe asthma. The publication was the lack of clinical complications and maintenance of stable lung function during a period of five years after BT, compatible with the profile of long-term safety of bluetongue.


    * The latest issue of Annals of Allergy, Asthma and Immunology, the article "The persistent efficacy of bronchial thermoplasty in patients with severe asthma," which is under www.annallergy.org. We present the results of the basic intervention Asthma Research 2 (AIR 2) of First Instance, which show the continued safety and efficacy of BT in two years.
"It is gratifying, the most important benefits of bronchial thermoplasty see consist of up to two years in patients with severe asthma in the AIR2 researched study," said Mario Castro, MD, professor of medicine and pediatrics at Washington University School of Medicine, Principal Investigator in the trial AIR2 AIR2 lead author of the paper. "These clinically meaningful improvements, combined with consistent long-term security and stable bronchial thermoplasty confirmed as an important treatment option for patients with severe asthma is not well controlled with currently available drugs."

In summary, bronchial thermoplasty, a strong safety profile of long-term, follow-up has shown up to five years in three successive trials. Besides safety, the results of two years of the study also show long-term effect AIR2 effect.

Alair Bronchial thermoplasty system, and more permanent control of asthma in adult patients with severe asthma, asthma is not good (inhaled drugs) in the fight against drugs in the course has been developed by Asthmatx, which was acquired by Boston Scientific in 2010 .

Related Posts by Categories

Widget by Hoctro | Jack Book